US20100040648A1 - Plasmids with immunological action - Google Patents

Plasmids with immunological action Download PDF

Info

Publication number
US20100040648A1
US20100040648A1 US12/377,114 US37711407A US2010040648A1 US 20100040648 A1 US20100040648 A1 US 20100040648A1 US 37711407 A US37711407 A US 37711407A US 2010040648 A1 US2010040648 A1 US 2010040648A1
Authority
US
United States
Prior art keywords
plasmid
seq
plasmid according
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/377,114
Inventor
Mara Gerloni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Investment and Patents SA
Original Assignee
International Investment and Patents SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Investment and Patents SA filed Critical International Investment and Patents SA
Assigned to INTERNATIONAL INVESTMENT AND PATENTS S.A. reassignment INTERNATIONAL INVESTMENT AND PATENTS S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GERLONI, MARA
Assigned to INTERNATIONAL INVESTMENT AND PATENTS S.A. reassignment INTERNATIONAL INVESTMENT AND PATENTS S.A. CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 022577 FRAME 0774. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ADDRESS IS 31, BOULEVARD GRANDE-DUCHESSE CHARLOTTE, LUXEMBOURG, LUXEMBOURG L-1331. Assignors: GERLONI, MARA
Publication of US20100040648A1 publication Critical patent/US20100040648A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the object of the present invention is represented by a recombinant plasmid usable for the transfection of eukaryotic and prokaryotic cells, having a length comprised between 7 and 12 kbases and comprising a sequence encoding the heavy chain of the immunoglobulin.
  • a further object of the invention is represented by the use of the aforesaid plasmid for the preparation of a pharmaceutical formulation, or of a vaccine or a therapeutic treatment, for inducing an immune response in a human or animal organism.
  • DNA of plasmidic origin may be used for the transfection of prokaryotic and eukaryotic cells through known methods.
  • the plasmids constructed for this purpose are generally constituted by a skeleton which has inserted units of genetic material encoding a certain protein which may or may not be provided with its own biological activity.
  • the plasmids may be of commercial origin, into which a part bearing the specificity is introduced into a structural construct that is already known and used, or generated autonomously, that is, by assembling fragments of selected genetic material on the basis of a certain profile to be reconstructed at the organism for which the plasmid is destined.
  • the synthesis of a plasmid is an operation of fundamental importance for the purpose of obtaining the desired cellular properties.
  • the plasmids determine the efficiency of the transfection and of the synthesis of the transgenic protein, and also the safety of the transfection, and therefore in the final analysis the resultant efficacy of the proteic expression of the transfected cell.
  • a plasmid is a vector of genetic data which influence the cellular cycle of the host cell and, consequently, the life cycle of the organism which hosts these transfected cells: the more data introduced into the plasmid, the more risks are run in the course of the transfection.
  • a plasmid is characterized by the specificity of the data contained: the less complex it is, the easier the synthesis thereof and the safer the use thereof.
  • a plasmid exercises the capacity of transfecting a cellular population more or less spontaneously depending on the type of cell and the experimental conditions of contact/incubation in which transfection is carried out. The more selective a plasmid is for a specific cellular population, the more it is usable in conditions of safety.
  • the conditions in which transfection is carried out are decisive for the success thereof: the homogeneity and the concentration of the cells to be transfected, the incubation time and conditions, the possibility of monitoring the phenomenon with specific and selective methods constitute an extremely important corollary for the success of the operation.
  • plasmid encoding immunogenic epitopes in an autologous transfection method is one of the systems that can be used for inducing a specific immune response in some pathologies characterized by the appearance of infecting agents, or by spontaneous or induced cellular mutation (carcinogenesis), with modification of the apoptotic course of a selected cell or cellular line.
  • WO 90/09804 describes immunoglobulins genetically engineered for expressing a predefined peptide epitope in the variable region or in the bond domain of the immunoglobulin.
  • WO 00/61766 describes tumoral antigens derived from telomerasis that can be used for generating a response mediated by T-cells against telomerasis and consequently against the tumour itself.
  • WO 00/64488 describes a plasmid encoding chimeric heavy chain of an immunoglobulin, the pN ⁇ 1 V H 62 plasmid, which is obtained by subcloning the murine V H 62 gene into the pN ⁇ 1 plasmid, containing a sequence encoding a human ⁇ 1 costant region.
  • This plasmid can be modified by introduction of heterologous epitopes in any of the complementarity determining regions of the variable region. Therefore, its use in a method for inducing an immunoresponse is disclosed.
  • the pN ⁇ 1 V H 62 plasmid contains portions that will be harmful if this plasmid would be injected into humans. Furthermore, the dimensions of this plasmid are such that a very low transfection yield is obtained.
  • FIG. 1 Map of Plasmid 1 where I-2483 bp is the segment encoding the variable region Vh62, 2484-5077 bp is the segment encoding the constant region ⁇ 1 , 6943-7737 bp is the segment encoding the gene for resistance to neomycin, and 9324-9267 bp is the E. coli origin of replication.
  • FIG. 2 Map of Plasmid 2 where 1 to 2775 is the segment encoding the variable region vh62, 161 to 907 is the viral promoter CMV, 2776-5366 bp is the segment encoding the constant region ⁇ 1 , 7232 to 8026 bp is the segment encoding the gene for resistance to neomycin and 8613 bp to 9553 bp is the E. coli origin of replication.
  • FIG. 3 Diagrammatic representation of a model of insertion of epitopes into the CDRs of the plasmid.
  • FIG. 4 Hypothesized structure of a protein with antigenic epitopes that is encoded by the plasmid described.
  • FIG. 5 Restriction map of the plasmids.
  • FIG. 6 Amplification by means of PCT test of the plasmid from lymphocytes transfected ex vivo.
  • the present inventors have now developed plasmids comprising a sequence encoding the heavy chain of immunoglobulin that do not present the drawbacks of the pN ⁇ 1 V H 62 plasmid when used for inducing an immunoresponse in vivo or ex vivo in a human or animal organism.
  • the plasmids developed have a better safety profile and show an increase yield when transfected into cells.
  • These plasmids have a length comprised between 7 and 12 kbases, preferably between 8 and 12 kbases, more preferably between 9 and 11 kbases and, even more preferably, between 9 and 10 kbases and are able to express the heavy chain of immunoglobulin when they are transfected into lymphocytes.
  • these plasmids express a chimeric heavy chain of immunoglobulin, preferably comprising a murine variable region and a human constant region, preferably Ig ⁇ 1 .
  • the murine variable region is preferably the V H region from hybridoma 62 derived from splenocytes of an adult hyperimmunised mouse (Zanetti et al. J. Immunol., 1983, 131:2452), hereinafter referred to as V H 62 region.
  • the V H 62 hybridoma 62 secretes a monoclonal antibody with anti-tyroglobulin activity
  • the Ig ⁇ 1 region gene is preferably cloned from the vector pN ⁇ 1 .
  • the plasmids may further contain a promoter specific for lymphocytic cells, preferably of around 50 bp, or of viral origin, preferably the CMV promoter.
  • the plasmids of the invention preferably also comprise the polyadenylation sequence AATAAA.
  • the plasmids of the invention do not express resistance to betalactamic antibiotics and in particular to ampicillin, and/or do not comprise a replication origin of SV40.
  • the plasmids preferably contain a replication origin of Escherichia coli , preferably PBR322. Furthermore, the plasmids preferably express resistance to neomycin.
  • Preferred plasmids of the invention are plasmids 1 and 2 .
  • the plasmid 1 has a length of 9727 bp (SEQ ID NO: 1 and FIG. 1 ) and the plasmid 2 of 10004 bp (SEQ ID NO: 2 and FIG. 2 ). Both the plasmids described encode a chimeric heavy chain of immunoglobulin.
  • the sole structural difference between the two plasmids is determined by the specific promoter, which in the case of the plasmid 1 is a specific promoter for lymphocytic cells of 50 bp, and in the case of the plasmid 2 is a viral promoter with dimension of 742 bp.
  • the skeleton of the plasmids is represented by pSV2neo, a DNA of bacterial origin containing the gene for resistance to neomycin and the origin of replication PBR322.
  • the genetic sequence encoding the heavy immunoglobulinic chain is composed of:
  • the immunoglobulinic promoter of the plasmid 1 is an integral part of V H 62, while the viral promoter of the plasmid 2 was derived from the plasmid phMGFP (Promega, Wis., USA).
  • the gene for resistance to neomycin also confers a resistance to kanamycin for selective growth in prokaryqtic cells.
  • the polyadenylation sequence is in position 5178:5183 of the plasmid and follows the human constant region.
  • the sequence is as follows: AATAAA.
  • the origin of bacterial replication is of Escherichia coli and is situated in position 8324:9264.
  • the particular feature of the plasmids of the invention is that the regions determining the complementarity (CDR) of the encoded protein may be mutagenized for the purpose of introducing therein epitopes (from 5 to 25 amino acid residues) with antigenic properties (Gerloni et al Nature Biotechnology 1997). Such properties make it possible to use the plasmid in question for inducing a specific immune response either by means of a transfection ex vivo with the inoculum of cells transfected spontaneously or by means of direct inoculation in vivo (genic immunization).
  • CDR complementarity
  • an object of the present invention is the use of the plasmids of the invention for the preparation of a pharmaceutical formulation for DNA vaccination, in particular for inducing an immunoresponse in a human or animal organism.
  • another object of the invention is a formulation containing at least one plasmid according to any one of the preceding claims together with pharmaceutically acceptable excipients and/or coadjuvants.
  • the formulation of the invention may be used for prophylactic or therapeutic purposes.
  • the formulation of the invention may be used in particular in a human or animal organism that is or was affected by:
  • a further object of the present invention is a method for inducing an immunoresponse in a human or animal organism.
  • Said method comprised transfection of prokaryotic and/or eukaryotic cells ex vivo and the subsequent inoculation of said prokaryotic and/or eukaryotic cells into said human or animal organism.
  • said transfected cells belong to the family of, limphocytes and are preferably taken from the peripheral vessels of said human or animal organism.
  • said method comprises inoculation of the plasmid in vivo into said human human or animal organism.
  • Inoculation of the plasmid or of the prokaryotic and/or eukaryotic cells into said human or animal organism is preferably carried out by means of injective or transmucosal administration.
  • the protein encoded by the plasmids of the invention like all the immunoglobulins, possesses 3 CDRs, CDR1 with a restriction site usable for the insertion of peptide sequences AfiIII, CDR2 with a Ncol site and CDR3 with an Acc65I site.
  • FIG. 3 An example of insertion of antigenic epitopes into the CDRs is shown in FIG. 3 .
  • antigenic epitopes preferred for the purposes of the present invention are:
  • the transgenic product encoded plasmids 1 and 2 is a protein with a molecular weight of around 156.000 daltons ( FIG. 4 ).
  • the heavy region encoded is chimeric in nature: part human (the constant region) and part murine (the variable region). Nevertheless, the murine part contains sequences 80% homologous with the human variable regions.
  • the aforesaid plasmids are also devoid of “useless” sequences (for example the sequence SV40 or pieces of genomic material) which would represent greater risks of homology with the genome of the host cell and therefore greater risks of integration in the cell itself.
  • the restriction map obtained by digestion with restriction enzymes is the first criterion to be considered in order to define the identity of a plasmid.
  • the map shown in FIG. 5 identifies in an exclusive manner the plasmids 1 and 2 .
  • the sequence of the plasmid 1 is shown in SEQ ID NO: 1
  • the sequence of the plasmid 2 is shown in SEQ ID NO: 2.
  • a plasmid encoding immunogenic epitopes in a method of transfection is one of the systems that can be used for inducing a specific immune response in some pathologies characterized by the appearance of infecting agents, or by spontaneous or induced cellular mutation (carcinogenesis), with modification of the apoptic course of a selected cell or cellular line.
  • a further use for such a plasmid is the direct injection in vivo into immuno-competent organisms in order to induce an immune response against proteins of a foreign nature and pathogenic microorganisms (Tang et al., Nature 1992, Ulmer et al., Science 1993, Gerloni et al., Nature Biotechnology 1997).
  • the induction of humoral responses (mediated by antibodies) and cellular mediated responses (mediated by T-lymphocytes of type CD4 and CD8) effective in the treatment or prevention of pathologies of infective and cancerous origin was demonstrated.
  • the essential components of a plasmid to be used in vivo are the gene encoding the antigen (or pieces thereof) of interest, a promoter sequence (normally derived from cytomegalovirus, CMV) which guides the transcription of the antigen, a region of polyadenylation which ensures the translation thereof.
  • a promoter sequence normally derived from cytomegalovirus, CMV
  • plasmids of bacterial origin contain sequences of non-methylated cytosine together with residues of guanosine (CpG). These CpG units have the capacity of increasing the immunogenic capacity of the plasmids themselves and therefore function as adjuvants.
  • nucleic acids into somatic cells appears to mimic the immunity induced by natural infections and offers various advantages, including the possibility of producing and testing such plasmids in an inexpensive, easy and rapid manner. Moreover, the plasmids are much more stable than conventional vaccines and may be preserved as lyophilisates.
  • the plasmid is usually inoculated in vivo by the intramuscular or intradermal route, although other routes such as the oral, vaginal, endovenous, intraperitoneal and subcutaneous routes are applicable.
  • the plasmids are administered in a variety of diluents which include distilled water, saline or sugar solutions, physiological buffers, isotonicising compounds, preservative or cryoprotective substances in case the processes of lyophilisation are necessary.
  • diluents include distilled water, saline or sugar solutions, physiological buffers, isotonicising compounds, preservative or cryoprotective substances in case the processes of lyophilisation are necessary.
  • the dose of plasmid used in the immunization protocols varies from case to case but, as a rule, amounts of from 25 to 200 ⁇ g per dose are used with 3 doses/injections at intervals of three weeks.
  • a further object of the present invention is therefore constituted by two recombinant plasmids characterized by a sequence corresponding to SEQ ID NO: 1 and SEQ ID NO: 2, respectively or a sequence at least 90% homologous, preferably 95% homologous to SEQ ID NO. 1 and SEQ ID NO: 2.
  • These plasmids have dimensions that are reduced but suitable for the purpose and a transfection method that is suitable, reproducible, safe and effective.
  • a further object of the present invention is constituted by the use of a method of transfection ex vivo without the use of any physical or chemical means which might facilitate the process.
  • a method of transfection ex vivo does not induce disturbances in the functionality of the transfected cells and does not induce genetic transformation thereof.
  • the method is characterized by separation of the specific cellular material to be transfected from the remainder of the corpuscular and fluid part of the peripheral blood, obtainable with processes with less handling than the normal centrifuging methods: the use of apheresis makes it possible to separate a large number of lymphocytic cells on which to carry out transfection in a manner which is painless for the patient and very much more useful for experimental purposes.
  • apheresis makes it possible to separate a large number of lymphocytic cells on which to carry out transfection in a manner which is painless for the patient and very much more useful for experimental purposes.
  • the isolation of the lymphocytes to be transfected may also be carried out by a classic method based on centrifuging; in that case the treatment of apheresis described above in item 1 and item 2 may be substituted by the following:
  • the use of the plasmid of reduced dimensions and a selected population of cells as described above makes it possible to obtain advantages from the process, such as a reduced time for handling of the blood and of its lymphocytic fraction, a reduced incubation time, a substantially reproducible process yield, the possibility of applying a high degree of automation to the various steps of the process and the possibility of performing the transfection process directly inside an isolated device which does not require the adoption of sterile conditions of the working ambience outside the device itself, which are required by the handling of biological fluids intended for human administration.
  • a object of the present invention is constituted by the use of a plasmid of contained dimension and characterized by the sequence described, with a method of isolation of the material to be transfected with reduced handling, with transfection conditions described for inducing immune responses in the treated patients against the agent responsible for the infection or the mutation, of which the specific imprint at the sequential and conformational level is contained in the genetic material represented in the plasmid.
  • a further object of the present invention is constituted by the use of a device in which to carry out the incubation of the plasmid with the cells, characterized by the presence of a space in which to accommodate the desired volume of cells, a port through which to insert a needle in order to deposit a solution of the plasmid and an optional other port through which to effect the sampling of the transfected cells.
  • the plasmid with the sequence shown in SEQ ID NO: 1 is used on a population of lymphocytic cells separated from the blood by the method of apheresis; these transfected cells, after incubation under the normal conditions used for biological fluids, are injected back into a patient in order to induce an immune type of response.
  • the plasmid constructed as described is used under the conditions described for transfecting a population of lymphocytic cells harvested by means of apheresis or centrifuging from a patient affected by a tumour of the pancreas, or prostate, lung, kidney, or skin, or affected by some other type of adenomatous or carcinomatous or other tumoral form, either solid or acytic in form, in order to induce in the patient himself a selective immune response against only the cancerous cells, expressing superficially the proteic fraction contained in the plasmid and by these caused to express the lymphocytes, used as APC (cells presenting the antigen).
  • APC cells presenting the antigen
  • the plasmid shown in SEQ ID NO: 1 is modified by the substitution of the promoter for lymphocytic cells with a promoter of viral origin (CMV).
  • CMV promoter of viral origin
  • Such substitution gives rise to a plasmid of slightly larger dimensions (300 bp), shown in SEQ ID NO: 2, and used for inducing an immune response in an organism by means of direct parenteral (intramuscular, intradermal, subcutaneous or endovenous) administration or transmucosal administration (via the nasal, oral, intestinal or vaginal mucosa).
  • the plasmid 1 was constructed according to the following protocol:
  • lymphocytes contained in the interface band, are harvested and transferred into a new tube and washed 3 times in PBS (without Ca ++ and Mg ++ ) with recovery by centrifuging.
  • lymphocytes An aliquot of lymphocytes is diluted 1:1 in tryptan blue and counted in a haemocytometer with the microscope in order to determine the vitality thereof (at least 90%).
  • the lymphocytes are re-suspended at a concentration of 20 ⁇ 10 6 cells per ml in PBS and aliquoted into plates provided with wells with U-shaped bases. There are then added 25 ⁇ g of a plasmid, having the sequence shown in SEQ ID NO: 1, and the plate is placed in an incubator for 60-90 minutes at 37° C. and 5% of CO 2 .
  • the cells are then diluted to a concentration of 1 ⁇ 10 6 cells per ml in suitable culture medium, placed in flasks inside an incubator and left for one night at 37° C. and 5% of CO 2 . After having verified that the cellular vitality is above 70%, the cells are washed twice in saline solution, the number of total cells containing the dose to be inoculated is then calculated, corresponding to a number of cells variable from 10,000 to 100 million and the latter are then re-suspended in an endovenous administration bag, which is then used for inoculation into the patient.
  • transfected lymphocytes An aliquot of the transfected lymphocytes is tested before use by means of the extraction of DNA and mRNA in a nested PCR test in such a way as to evaluate the transfection of lymphocytes that has occurred and give a quantification thereof, even approximate.
  • FIG. 6 shows the amplification with a PCR test of the DNA from human lymphocytes transfected with plasmidic DNA.
  • Ladder is the reference for the determination of the dimension of the amplified fragments.
  • the numbers refer to the number of cells amplified, and Na ⁇ ve means lymphocytes not transfected with DNA (negative control).
  • the figure demonstrates the transfection of the patient's lymphocytes which has taken place, and above all denotes its specificity, inasmuch as no fragment is amplified from lymphocytes not subjected to transfection.
  • lymphocytes transfected with a DNA encoding antigenic sequences are capable of evoking an immune response after inoculation into laboratory animals and that the plasmid of the present invention, shown in SEQ ID NO: 1, encodes an epitope capable of evoking a cellular response on the part of the T CD4 lymphocytes, in order to verify the biological activity of the lymphocytes transfected by DNA, an experiment was planned for the verification of the immunogenicity of such lymphocytes in-vivo, devised as described hereinafter.
  • the experiment described above shows a specific immune response induced in mice when immunized with lymphocytes transfected with the plasmidic DNA, proving a clear biological property thereof when used in a test in vivo.
  • mice were inoculated intramuscularly, in the quadriceps, with 100 ⁇ g of DNA diluted in 100 ⁇ l of saline solution (group A).
  • the immunization protocol consisted of a total of 3 injections separated by three weeks' interval.
  • Another group of 10 C57/B16 were immunized in the same way, using the same plasmid with the CDRs empty (without any epitope) (group B) as control of specificity of the vaccination;

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Recombinant plasmids usable for the transfection of eukaryotic and prokaryotic cells are described; such plasmids have a length comprised between 7 and 12 kbases and comprise a sequence encoding the heavy chain of an immunoglobulin; in particular, they may be used:
    • in a process of transfection of prokaryotic or eukaryotic cells (ex vivo) which can be inoculated into higher organisms in order to induce a prophylactic or therapeutic immune response;
    • in a protocol of direct inoculation (in vivo) in higher organisms in genic immunization methodologies with the aim of evoking prophylactic or therapeutic immune responses.

Description

    CROSS-REFERENCE TO PRIOR APPLICATIONS
  • This is a U.S. National Phase Application under 35 U.S.C. §371 of International Patent Application No. PCT/EP2007/057224 filed Jul. 13, 2007, which claims the benefit of European Patent Application No. 06118717.5, filed Aug. 10, 2006, both of which are incorporated by reference herein. The International Application was published in English on Feb. 14, 2008 as WO 2008/017568 A1 under PCT Article 21(2).
  • The object of the present invention is represented by a recombinant plasmid usable for the transfection of eukaryotic and prokaryotic cells, having a length comprised between 7 and 12 kbases and comprising a sequence encoding the heavy chain of the immunoglobulin. A further object of the invention is represented by the use of the aforesaid plasmid for the preparation of a pharmaceutical formulation, or of a vaccine or a therapeutic treatment, for inducing an immune response in a human or animal organism.
  • In particular, described and claimed is a sequence of bases that are used for the construction of plasmids which may be used:
      • in a process of transfection of prokaryotic or eukaryotic cells (ex vivo) which can be inoculated into higher organisms in order to induce a prophylactic or therapeutic immune response (in particular by means of the plasmid 1 having the sequence SEQ ID NO: 1);
      • in a protocol of direct inoculation (in vivo) into higher organisms in genic immunization methodologies in order to evoke prophylactic or therapeutic immune responses (in particular by means of the plasmid 2 having the sequence SEQ ID NO: 2).
  • A description is also given of a profile of pathologies which may be treated with the plasmids described.
    • STATE OF THE ART
  • DNA of plasmidic origin may be used for the transfection of prokaryotic and eukaryotic cells through known methods. The plasmids constructed for this purpose are generally constituted by a skeleton which has inserted units of genetic material encoding a certain protein which may or may not be provided with its own biological activity.
  • The plasmids may be of commercial origin, into which a part bearing the specificity is introduced into a structural construct that is already known and used, or generated autonomously, that is, by assembling fragments of selected genetic material on the basis of a certain profile to be reconstructed at the organism for which the plasmid is destined.
  • The synthesis of a plasmid is an operation of fundamental importance for the purpose of obtaining the desired cellular properties. The plasmids determine the efficiency of the transfection and of the synthesis of the transgenic protein, and also the safety of the transfection, and therefore in the final analysis the resultant efficacy of the proteic expression of the transfected cell.
  • A plasmid is a vector of genetic data which influence the cellular cycle of the host cell and, consequently, the life cycle of the organism which hosts these transfected cells: the more data introduced into the plasmid, the more risks are run in the course of the transfection.
  • A plasmid is characterized by the specificity of the data contained: the less complex it is, the easier the synthesis thereof and the safer the use thereof.
  • A plasmid exercises the capacity of transfecting a cellular population more or less spontaneously depending on the type of cell and the experimental conditions of contact/incubation in which transfection is carried out. The more selective a plasmid is for a specific cellular population, the more it is usable in conditions of safety.
  • The conditions in which transfection is carried out are decisive for the success thereof: the homogeneity and the concentration of the cells to be transfected, the incubation time and conditions, the possibility of monitoring the phenomenon with specific and selective methods constitute an extremely important corollary for the success of the operation.
  • In the specific case in which a plasmid is used for transfecting cells to be injected in vivo in patients, such cells are to be handled with extreme caution inasmuch as they must be re-inserted into the patient, and risky and fatal collateral phenomena cannot be risked: the less handling is necessary, the greater the safety of the method and the more reproducible the result.
  • From the above it inevitably follows that the use of a plasmid of reduced dimensions, especially if combined with a method with limited handling, is a condition to be preferred in transfection used for prophylactic and therapeutic purposes.
  • The use of a plasmid encoding immunogenic epitopes in an autologous transfection method is one of the systems that can be used for inducing a specific immune response in some pathologies characterized by the appearance of infecting agents, or by spontaneous or induced cellular mutation (carcinogenesis), with modification of the apoptotic course of a selected cell or cellular line.
  • WO 90/09804 describes immunoglobulins genetically engineered for expressing a predefined peptide epitope in the variable region or in the bond domain of the immunoglobulin.
  • WO 00/61766 describes tumoral antigens derived from telomerasis that can be used for generating a response mediated by T-cells against telomerasis and consequently against the tumour itself.
  • WO 00/64488 describes a plasmid encoding chimeric heavy chain of an immunoglobulin, the pNγ1VH62 plasmid, which is obtained by subcloning the murine VH62 gene into the pNγ1 plasmid, containing a sequence encoding a human γ1 costant region. This plasmid can be modified by introduction of heterologous epitopes in any of the complementarity determining regions of the variable region. Therefore, its use in a method for inducing an immunoresponse is disclosed.
  • However, the pNγ1VH62 plasmid contains portions that will be harmful if this plasmid would be injected into humans. Furthermore, the dimensions of this plasmid are such that a very low transfection yield is obtained.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1: Map of Plasmid 1 where I-2483 bp is the segment encoding the variable region Vh62, 2484-5077 bp is the segment encoding the constant region γ1, 6943-7737 bp is the segment encoding the gene for resistance to neomycin, and 9324-9267 bp is the E. coli origin of replication.
  • FIG. 2: Map of Plasmid 2 where 1 to 2775 is the segment encoding the variable region vh62, 161 to 907 is the viral promoter CMV, 2776-5366 bp is the segment encoding the constant region γ1, 7232 to 8026 bp is the segment encoding the gene for resistance to neomycin and 8613 bp to 9553 bp is the E. coli origin of replication.
  • FIG. 3: Diagrammatic representation of a model of insertion of epitopes into the CDRs of the plasmid.
  • FIG. 4: Hypothesized structure of a protein with antigenic epitopes that is encoded by the plasmid described.
  • FIG. 5: Restriction map of the plasmids.
  • FIG. 6: Amplification by means of PCT test of the plasmid from lymphocytes transfected ex vivo.
    •  DESCRIPTION OF THE INVENTION
  • The present inventors have now developed plasmids comprising a sequence encoding the heavy chain of immunoglobulin that do not present the drawbacks of the pNγ1VH62 plasmid when used for inducing an immunoresponse in vivo or ex vivo in a human or animal organism. In particular, the plasmids developed have a better safety profile and show an increase yield when transfected into cells.
  • These plasmids have a length comprised between 7 and 12 kbases, preferably between 8 and 12 kbases, more preferably between 9 and 11 kbases and, even more preferably, between 9 and 10 kbases and are able to express the heavy chain of immunoglobulin when they are transfected into lymphocytes.
  • According to a preferred embodiment, these plasmids express a chimeric heavy chain of immunoglobulin, preferably comprising a murine variable region and a human constant region, preferably Igγ1. The murine variable region is preferably the VH region from hybridoma 62 derived from splenocytes of an adult hyperimmunised mouse (Zanetti et al. J. Immunol., 1983, 131:2452), hereinafter referred to as VH62 region. The VH62 hybridoma 62 secretes a monoclonal antibody with anti-tyroglobulin activity
  • The Igγ1 region gene is preferably cloned from the vector pNγ1.
  • The plasmids may further contain a promoter specific for lymphocytic cells, preferably of around 50 bp, or of viral origin, preferably the CMV promoter.
  • The plasmids of the invention preferably also comprise the polyadenylation sequence AATAAA.
  • It is preferred that the plasmids of the invention do not express resistance to betalactamic antibiotics and in particular to ampicillin, and/or do not comprise a replication origin of SV40.
  • Accordingly, the plasmids preferably contain a replication origin of Escherichia coli, preferably PBR322. Furthermore, the plasmids preferably express resistance to neomycin.
  • Preferred plasmids of the invention are plasmids 1 and 2.
  • The plasmid 1 has a length of 9727 bp (SEQ ID NO: 1 and FIG. 1) and the plasmid 2 of 10004 bp (SEQ ID NO: 2 and FIG. 2). Both the plasmids described encode a chimeric heavy chain of immunoglobulin.
  • The sole structural difference between the two plasmids is determined by the specific promoter, which in the case of the plasmid 1 is a specific promoter for lymphocytic cells of 50 bp, and in the case of the plasmid 2 is a viral promoter with dimension of 742 bp.
  • The skeleton of the plasmids is represented by pSV2neo, a DNA of bacterial origin containing the gene for resistance to neomycin and the origin of replication PBR322.
  • The genetic sequence encoding the heavy immunoglobulinic chain is composed of:
      • a murine variable region (VH62) of around 2.5 kb, originally cloned from a mouse hybridoma (hybridoma 62) secreting a monoclonal antibody with anti-tyroglobulin activity (Sollazzo, et. al., Eur. J. Immunol., 1989);
      • a human Igγ1 constant region deriving from the pNγ1 vector (Hybritech Corporation, San Diego, Calif.).
  • The immunoglobulinic promoter of the plasmid 1 is an integral part of VH62, while the viral promoter of the plasmid 2 was derived from the plasmid phMGFP (Promega, Wis., USA). The gene for resistance to neomycin also confers a resistance to kanamycin for selective growth in prokaryqtic cells.
  • The polyadenylation sequence is in position 5178:5183 of the plasmid and follows the human constant region. The sequence is as follows: AATAAA. The origin of bacterial replication is of Escherichia coli and is situated in position 8324:9264.
  • The particular feature of the plasmids of the invention is that the regions determining the complementarity (CDR) of the encoded protein may be mutagenized for the purpose of introducing therein epitopes (from 5 to 25 amino acid residues) with antigenic properties (Gerloni et al Nature Biotechnology 1997). Such properties make it possible to use the plasmid in question for inducing a specific immune response either by means of a transfection ex vivo with the inoculum of cells transfected spontaneously or by means of direct inoculation in vivo (genic immunization).
  • Accordingly, an object of the present invention is the use of the plasmids of the invention for the preparation of a pharmaceutical formulation for DNA vaccination, in particular for inducing an immunoresponse in a human or animal organism. Furthermore, another object of the invention is a formulation containing at least one plasmid according to any one of the preceding claims together with pharmaceutically acceptable excipients and/or coadjuvants.
  • The formulation of the invention may be used for prophylactic or therapeutic purposes.
  • The formulation of the invention may be used in particular in a human or animal organism that is or was affected by:
      • tumours belonging to the family of carcinomas and/or adenomas and/or sarcomas and/or lipomas and/or solid and/or ascitic tumours, by prostate or pancreatic, renal or pulmonary carcinoma. Preferably, in this case said organism is or was affected by the presence of tumour cells having on the surface at least one antigenic epitope, the encoding sequence of which is contained in the plasmid.
      • bacterial, viral, fungal and/or parasitic infections.
  • A further object of the present invention is a method for inducing an immunoresponse in a human or animal organism. Said method comprised transfection of prokaryotic and/or eukaryotic cells ex vivo and the subsequent inoculation of said prokaryotic and/or eukaryotic cells into said human or animal organism. Preferably, said transfected cells belong to the family of, limphocytes and are preferably taken from the peripheral vessels of said human or animal organism. Alternatively, said method comprises inoculation of the plasmid in vivo into said human human or animal organism.
  • Inoculation of the plasmid or of the prokaryotic and/or eukaryotic cells into said human or animal organism is preferably carried out by means of injective or transmucosal administration.
  • The protein encoded by the plasmids of the invention, like all the immunoglobulins, possesses 3 CDRs, CDR1 with a restriction site usable for the insertion of peptide sequences AfiIII, CDR2 with a Ncol site and CDR3 with an Acc65I site.
  • It is therefore possible to insert into them various peptide sequences capable of evoking various immune responses both of the humoral type (mediated by B cells) and of the cellular mediated type (mediated by T-cells CD4 and CD8); for example, it is possible to insert at least a single sequence on each CDR, for a total of three sequences capable of evoking various immune responses; it is further possible to insert one or more sequences, optionally fused with one another, on each CDR.
  • An example of insertion of antigenic epitopes into the CDRs is shown in FIG. 3.
  • The antigenic epitopes preferred for the purposes of the present invention are:
      • tumoral antigens, such as for example that of telomerasis and, even more preferably, p540 (ILAKFLHWL; SEQ. ID NO: 3), p572 (RLFFYRKSV; SEQ. ID NO: 4), pY572 (YLFFYRKSV; SEQ. ID NO: 5) and p865 (RLVDDFLLV; SEQ. ID NO: 6);
      • antigens deriving from infective microorganisms, such as, for example, that of influenza and, preferably, the epitope pNP (ASNENMETM; SEQ. ID NO: 7).
  • The transgenic product encoded plasmids 1 and 2 is a protein with a molecular weight of around 156.000 daltons (FIG. 4). The heavy region encoded is chimeric in nature: part human (the constant region) and part murine (the variable region). Nevertheless, the murine part contains sequences 80% homologous with the human variable regions.
  • Important characteristics of the aforesaid plasmids are the absence of the gene for resistance to ampicillin and the presence of the gene for resistance to kanamycin which provides for the safe use thereof in subjects with potential allergies to the betalactamic antibiotics. Another advantageous factor is that kanamycin is an antibiotic stable at 37° C. (conditions of culture of the plasmid) for 24-48 hours, while ampicillin is stable only for 3-4 hours, consequently allowing a culture yield of the plasmid which is greater (less expensive production) and more stable.
  • The aforesaid plasmids are also devoid of “useless” sequences (for example the sequence SV40 or pieces of genomic material) which would represent greater risks of homology with the genome of the host cell and therefore greater risks of integration in the cell itself.
    • Analysis of the Restriction Map of the Plasmids
  • The restriction map obtained by digestion with restriction enzymes is the first criterion to be considered in order to define the identity of a plasmid. In particular, the map shown in FIG. 5 identifies in an exclusive manner the plasmids 1 and 2. There is also shown in succession an image of the fragments of the plasmid 1 after digestion, run on agarose gel in parallel with a standard of known dimension (1 Kb ladder) in order to determine the exact dimension thereof. The sequence of the plasmid 1 is shown in SEQ ID NO: 1, while the sequence of the plasmid 2 is shown in SEQ ID NO: 2.
    • Biological Characterization of the Plasmids
  • It has already been indicated previously that a plasmid encoding immunogenic epitopes in a method of transfection is one of the systems that can be used for inducing a specific immune response in some pathologies characterized by the appearance of infecting agents, or by spontaneous or induced cellular mutation (carcinogenesis), with modification of the apoptic course of a selected cell or cellular line.
  • A further use for such a plasmid is the direct injection in vivo into immuno-competent organisms in order to induce an immune response against proteins of a foreign nature and pathogenic microorganisms (Tang et al., Nature 1992, Ulmer et al., Science 1993, Gerloni et al., Nature Biotechnology 1997). In this field with the inoculation of functional genes the induction of humoral responses (mediated by antibodies) and cellular mediated responses (mediated by T-lymphocytes of type CD4 and CD8) effective in the treatment or prevention of pathologies of infective and cancerous origin was demonstrated.
  • Consequently, the concept of genic immunization is now adopted by vaccinologists all over the world, who use plasmids encoding antigens deriving from bacteria, viruses and parasites and also from various types of tumour in order to evoke specific and protective immune responses. Clinical trials are currently under way for the therapy or prophylaxis of HIV, herpes, influenza, avian influenza, SARS, hepatitis B and C and carcinomas of various kinds.
  • The essential components of a plasmid to be used in vivo are the gene encoding the antigen (or pieces thereof) of interest, a promoter sequence (normally derived from cytomegalovirus, CMV) which guides the transcription of the antigen, a region of polyadenylation which ensures the translation thereof.
  • Furthermore, together with the origin of replication for the amplification of the plasmid in bacterial cells there is also a gene which encodes antibiotic resistance in order to ensure the selection of the bacterial population and to eliminate contamination during culture.
  • Another intrinsic property of the DNA vaccines is that plasmids of bacterial origin contain sequences of non-methylated cytosine together with residues of guanosine (CpG). These CpG units have the capacity of increasing the immunogenic capacity of the plasmids themselves and therefore function as adjuvants.
  • The direct inoculation of nucleic acids into somatic cells appears to mimic the immunity induced by natural infections and offers various advantages, including the possibility of producing and testing such plasmids in an inexpensive, easy and rapid manner. Moreover, the plasmids are much more stable than conventional vaccines and may be preserved as lyophilisates.
  • The plasmid is usually inoculated in vivo by the intramuscular or intradermal route, although other routes such as the oral, vaginal, endovenous, intraperitoneal and subcutaneous routes are applicable.
  • The plasmids are administered in a variety of diluents which include distilled water, saline or sugar solutions, physiological buffers, isotonicising compounds, preservative or cryoprotective substances in case the processes of lyophilisation are necessary.
  • The dose of plasmid used in the immunization protocols varies from case to case but, as a rule, amounts of from 25 to 200 μg per dose are used with 3 doses/injections at intervals of three weeks.
  • A further object of the present invention is therefore constituted by two recombinant plasmids characterized by a sequence corresponding to SEQ ID NO: 1 and SEQ ID NO: 2, respectively or a sequence at least 90% homologous, preferably 95% homologous to SEQ ID NO. 1 and SEQ ID NO: 2. These plasmids have dimensions that are reduced but suitable for the purpose and a transfection method that is suitable, reproducible, safe and effective.
  • The use of such plasmids has specific characteristics:
      • optimum yield in the production process, inasmuch as a plasmid of measured content is simpler to produce and gives rise to better production yields if reduced in amplitude;
      • optimum stability of the cellular culture, since the plasmids contains the gene for resistance to antibiotic kanamycin stable at 37° C. for 24-48 hours (as opposed to ampicillin stable only for 4-6 hours at the same temperature) the stability of the bacterial culture is consequently significantly increased, with undoubted advantages in terms of yield;
      • high efficiency of spontaneous transfection (capacity of penetration into the cell) because of contained molecular dimensions and lesser steric bulk, a not negligible detail in the case of protocols in which the use of spontaneous transfection is envisaged;
      • the absence of the possibility of anaphylactic reactions that can be induced in the subjects treated, if predisposed to an allergic reaction to ampicillin, inasmuch as the plasmid, not possessing the gene for resistance to ampicillin, is not grown in the presence of that antibiotic;
      • low, if not zero, possibility of integration in the genome of the host cell inasmuch as the minimum quantity of plasmid used for transfection renders practically negligible the risk of integration (consequently reduced possibility of induction of oncogenic mutations in the host cell);
      • low, if not zero, possibility of direct integration in the genome of the host cell inasmuch as the plasmid does not possess extraneous sequences (such as SV40) which could have homologies with the genome of the cell itself and represent greater risks of integration;
      • high flexibility of use of the plasmid also for direction injection in vivo in genic immunization protocols. In fact, by substituting in the nucleotidic sequence the specific promoter for B cells with a viral promoter (CMV) with wider expression, the use of the plasmid is extended by simple transfection ex vivo to the use of direct inoculation in higher organisms.
  • A further object of the present invention is constituted by the use of a method of transfection ex vivo without the use of any physical or chemical means which might facilitate the process. Such a method does not induce disturbances in the functionality of the transfected cells and does not induce genetic transformation thereof. The method is characterized by separation of the specific cellular material to be transfected from the remainder of the corpuscular and fluid part of the peripheral blood, obtainable with processes with less handling than the normal centrifuging methods: the use of apheresis makes it possible to separate a large number of lymphocytic cells on which to carry out transfection in a manner which is painless for the patient and very much more useful for experimental purposes. In fact:
      • it does not disturb the functionality of the cells with gravitational or mechanical shocks;
      • it allows the harvesting of a large number of cells, to be used for the process and to keep stored as reference for the subsequent phase of therapeutic monitoring;
      • it does not impoverish the functional and structural resources of the patient or his coagulative or reparative processes;
      • it does not add any risk of contamination of the biological material and/or of the patient.
  • An object of the present invention is constituted by the use of a plasmid as described for effecting the transfection ex vivo of selected cells by means of a spontaneous process with the adoption of the following modalities:
    • 1. transfer of the peripheral blood originating from a patient into an instrument capable of directly separating the family of lymphocytes from the rest of the corpuscular fraction and from the serum (apheresis process);
    • 2. isolation of a quantity of lymphocytic cells suitable for the application of the treatment described hereinafter; then transfer of the isolated lymphocytes and washing with PBS (without Ca++ and Mg++) and further centrifuging;
    • 3. dilution 1:1 with tryptan blue and counting of the lymphocytes via haemocytometer and microscope in order to verify that they have preserved at least 90% of vitality;
    • 4. re-suspension of the lymphocytes at a concentration of around 20×106 cells/ml in PBS (without Ca++ and Mg++) and re-division of an aliquot into plates with U-shaped wells, where 25 μg of a plasmid having the sequence shown in SEQ ID NO: 1 are added;
    • 5. incubation of the plates with the transfection wells in an incubator for 30-90 minutes at 37° C. and 5% of CO2;
    • 6. transfer of a suitable aliquot of cells treated with plasmid into a suitable culture medium and leaving to incubate for one night;
    • 7. verifying that the cellular vitality is maintained above a threshold judged to be appropriate (typically 70%) and calculating the dose to be transferred to the patient;
    • 8. transfer into a phleboclysis bag of a suitable volume of transfected cells containing the dose to be re-administered to the patient (typically variable from a few thousands to a few tens of millions of cells);
    • 9. within the scope of the treatment intended to arouse an immune response against the cells which express at the surface the proteins of which the epitopes are contained in the plasmid, inoculation into the patient of the blood contained in the bag, transgenized by means of the use of the plasmid having the sequence shown in SEQ ID NO: 1.
  • As an alternative to the method described above, the isolation of the lymphocytes to be transfected may also be carried out by a classic method based on centrifuging; in that case the treatment of apheresis described above in item 1 and item 2 may be substituted by the following:
      • 1. transfer of the peripheral blood originating from a patient into test tubes, addition of buffer with Ficoll and centrifuging until the lymphocytes stratify into an unmistakable band;
      • 2. transfer of the isolated lymphocytes and washing with PBS (without Ca++ and Mg++) and further centrifuging.
  • The use of the plasmid of reduced dimensions and a selected population of cells as described above makes it possible to obtain advantages from the process, such as a reduced time for handling of the blood and of its lymphocytic fraction, a reduced incubation time, a substantially reproducible process yield, the possibility of applying a high degree of automation to the various steps of the process and the possibility of performing the transfection process directly inside an isolated device which does not require the adoption of sterile conditions of the working ambience outside the device itself, which are required by the handling of biological fluids intended for human administration.
  • A object of the present invention is constituted by the use of a plasmid of contained dimension and characterized by the sequence described, with a method of isolation of the material to be transfected with reduced handling, with transfection conditions described for inducing immune responses in the treated patients against the agent responsible for the infection or the mutation, of which the specific imprint at the sequential and conformational level is contained in the genetic material represented in the plasmid.
  • A further object of the present invention is constituted by the use of a device in which to carry out the incubation of the plasmid with the cells, characterized by the presence of a space in which to accommodate the desired volume of cells, a port through which to insert a needle in order to deposit a solution of the plasmid and an optional other port through which to effect the sampling of the transfected cells.
  • In a typical application of the present invention, the plasmid with the sequence shown in SEQ ID NO: 1 is used on a population of lymphocytic cells separated from the blood by the method of apheresis; these transfected cells, after incubation under the normal conditions used for biological fluids, are injected back into a patient in order to induce an immune type of response.
  • In a further application of the present invention, the plasmid constructed as described is used under the conditions described for transfecting a population of lymphocytic cells harvested by means of apheresis or centrifuging from a patient affected by a tumour of the pancreas, or prostate, lung, kidney, or skin, or affected by some other type of adenomatous or carcinomatous or other tumoral form, either solid or acytic in form, in order to induce in the patient himself a selective immune response against only the cancerous cells, expressing superficially the proteic fraction contained in the plasmid and by these caused to express the lymphocytes, used as APC (cells presenting the antigen).
  • In a further application of the present invention, the plasmid shown in SEQ ID NO: 1 is modified by the substitution of the promoter for lymphocytic cells with a promoter of viral origin (CMV). Such substitution gives rise to a plasmid of slightly larger dimensions (300 bp), shown in SEQ ID NO: 2, and used for inducing an immune response in an organism by means of direct parenteral (intramuscular, intradermal, subcutaneous or endovenous) administration or transmucosal administration (via the nasal, oral, intestinal or vaginal mucosa).
  • The plasmids described were evaluated for:
      • 1. the capacity for spontaneously transfecting human lymphocytes;
      • 2. the capacity for inducing an immune response in laboratory mice when injected with transfected cells ex vivo;
      • 3. the capacity for inducing an immune response in laboratory mice when injected directly with the plasmid 2 in a genic immunization protocol.
  • The following examples are intended purely as non-limiting illustrations of the invention.
  • The plasmid 1 was constructed according to the following protocol:
  • 1. Modification of the plasmid PSV2 neo
      • The plasmid PSV2 neo was digested with the restriction enzymes AhdI and XmnI in order to remove the segment for resistance to ampicillin (ampr)
      • PSV2 neo (ampr and SV40 minus) was digested with BsmBI and HindIII in order to remove the origin of replication SV40 (SV40)
      • PSV2 neo (ampr and SV40 minus) was digested with AatII and BstBI. At the end of this process a fragment of 2737 pairs of bases containing the origin of replication of E. Coli and the gene for resistance to neomycin/kanamycin was obtained. This fragment was isolated from agarose gel, purified on a column and maintained at 4° C. until subsequent use.
        2. Modification of the plasmid γ1Vh62
      • The plasmid γ1VH62 was digested with the restriction enzymes Fsel and BamHI in order to remove the segment of 4787 pairs of bases encoding human genomic DNA
      • The plasmid thus derived (DNAgenomicminus) was circularised with the new dimension of 10721 pairs of bases. It was digested with AatII and BstBI and the fragment containing the variable and constant region was purified for the subsequent ligation reaction
        3. Construction of the final plasmid 1
      • The plasmid PSV2 neo (ampr and SV40minus) deriving from the passage 1 was digested with AatII and BstBI.
      • The modified plasmid γ1VH62(DNAgenomicminus) deriving from the passage 2 was digested with AatII and BstBI.
      • The two modified plasmids thus digested were bonded together and used for transfecting competent cells of E. coli.
      • The plasmidic DNA extracted from the cells of E. coli was then used for the tests of identification by means of PCR, restriction map and sequencing.
        4. Construction of the final plasmid 2
      • The plasmid 1 was digested with DraII and BclI in order to remove the immunoglobulinic promoter contained therein
      • From the plasmid phMGFP, by the same digestion, the viral promoter CMV was removed
      • To the plasmid 1, without promoter, by means of PCR, the promoter CMV was added so as to obtain the plasmid 2.
  • The following examples are intended purely as a non-limiting illustration of the invention.
    • Example 1
  • An aliquot of around 50 ml of peripheral blood originating from a patient, with the addition of a suitable aliquot of anticoagulant, is transferred into 50 ml tubes, diluted 1:1 with buffer, 20 ml of Ficoll-Paque™ are added and centrifuging is carried out for 20 minutes at 2000 rpm.
  • After centrifuging the lymphocytes, contained in the interface band, are harvested and transferred into a new tube and washed 3 times in PBS (without Ca++ and Mg++) with recovery by centrifuging.
  • An aliquot of lymphocytes is diluted 1:1 in tryptan blue and counted in a haemocytometer with the microscope in order to determine the vitality thereof (at least 90%).
  • After the count, the lymphocytes are re-suspended at a concentration of 20×106 cells per ml in PBS and aliquoted into plates provided with wells with U-shaped bases. There are then added 25 μg of a plasmid, having the sequence shown in SEQ ID NO: 1, and the plate is placed in an incubator for 60-90 minutes at 37° C. and 5% of CO2.
  • The cells are then diluted to a concentration of 1×106 cells per ml in suitable culture medium, placed in flasks inside an incubator and left for one night at 37° C. and 5% of CO2. After having verified that the cellular vitality is above 70%, the cells are washed twice in saline solution, the number of total cells containing the dose to be inoculated is then calculated, corresponding to a number of cells variable from 10,000 to 100 million and the latter are then re-suspended in an endovenous administration bag, which is then used for inoculation into the patient.
  • An aliquot of the transfected lymphocytes is tested before use by means of the extraction of DNA and mRNA in a nested PCR test in such a way as to evaluate the transfection of lymphocytes that has occurred and give a quantification thereof, even approximate.
  • FIG. 6 shows the amplification with a PCR test of the DNA from human lymphocytes transfected with plasmidic DNA. Ladder is the reference for the determination of the dimension of the amplified fragments. The numbers refer to the number of cells amplified, and Naïve means lymphocytes not transfected with DNA (negative control). The figure demonstrates the transfection of the patient's lymphocytes which has taken place, and above all denotes its specificity, inasmuch as no fragment is amplified from lymphocytes not subjected to transfection.
    • Example 2
  • Proceeding from the assumption that the lymphocytes transfected with a DNA encoding antigenic sequences are capable of evoking an immune response after inoculation into laboratory animals and that the plasmid of the present invention, shown in SEQ ID NO: 1, encodes an epitope capable of evoking a cellular response on the part of the T CD4 lymphocytes, in order to verify the biological activity of the lymphocytes transfected by DNA, an experiment was planned for the verification of the immunogenicity of such lymphocytes in-vivo, devised as described hereinafter.
      • 4 C57/B16 mice were inoculated with 5,000 murine lymphocytes transfected with the plasmid as described in the protocol contained in the present invention. Inoculation was carried out endovenously in the tail vein;
      • 14 days after inoculation, the mice were sacrificed and the cells of the spleen were used in a test of proliferation in the presence of the epitope encoded by the plasmid used for transfection;
      • the splenocytes were cultured for 72 hours with the epitope of reference, and then tritiated timidine (a radioisotope capable of showing the cellular proliferation) was added thereto;
      • after 18 hours, the cells were harvested and the radioactivity measured with a beta counter instrument. The proliferation was expressed as stimulation index (SI), which is calculated by dividing the radioactive counts in the presence of the specific epitope by the radioactive counts in the presence of an uncorrelated epitope (non-specific proliferation). Conventionally, an SI of more than 3 is considered positive.
  • TABLE I
    example of immune response induced by the
    inoculation into laboratory animals of lymphocytes
    transfected with the plasmid in question. The specific
    peptide refers to the epitope encoded by the DNA
    incorporated in the plasmid of the invention, the
    control peptide has an uncorrelated sequence.
    SI SI
    Mouse Control peptide Specific peptide
    #
    1 0.8 11.8
    #2 1.3 14.3
    #3 1 13.3
    #4 1.1 16.3
  • The experiment described above shows a specific immune response induced in mice when immunized with lymphocytes transfected with the plasmidic DNA, proving a clear biological property thereof when used in a test in vivo.
    • Example 3
  • Using a plasmid as having the sequence shown in SEQ ID NO: 2, 10 C57/B16 mice were inoculated intramuscularly, in the quadriceps, with 100 μg of DNA diluted in 100 μl of saline solution (group A). The immunization protocol consisted of a total of 3 injections separated by three weeks' interval. Another group of 10 C57/B16 were immunized in the same way, using the same plasmid with the CDRs empty (without any epitope) (group B) as control of specificity of the vaccination;
      • 14 days after the last inoculation, the mice were sacrificed and the cells of the spleen were used in a test of cytotoxicity in comparison with cells pulsed with epitope (NP) encoded by the plasmid used for transfection. The specific epitope is a cytotoxic sequence of the nucleoprotein of Influenza Virus A/PR8;
      • the splenocytes were cultured for 5 days with the epitope of reference and then used as effectric cells in a cytotoxidity test;
      • the cytotoxicity test consists in measuring the radioactivity (51Cr) released by cells (EL-4) pulsed with epitope NP which are killed by the effectric cells from the immunized mice; the cytotoxicity is expressed as a percentage of lysis at a certain ratio of Effectrics:Target (E:T), which is calculated by dividing the amount of radioactivity released by the cells pulsed with the peptide by the amount of radioactivity released by the non-pulsed cells (specific cytotoxicity).
  • TABLE II
    Example of cytotoxicity mediated by specific
    T CD8 cells in animals immunized with the plasmidic DNA
    #
    2.
    Group % of specific lysis
    A 50% + 12
    B (control) 3% + 2

    plasmidic DNA, proving a clear biological property thereof when used in a test in vivo.

Claims (37)

1.-31. (canceled)
32. A recombinant plasmid having a length of between 7 and 12 kilobases and comprising a sequence encoding the heavy chain of immunoglobulin, wherein the plasmid contains at least one sequence encoding an antigenic epitope and the plasmid does not express resistance to a betalactamic antibiotic.
33. The plasmid according to claim 32, wherein said betalactamic antibiotic is ampicillin.
34. The plasmid according to claim 32, wherein it has a length of between 8 and 12 kilobases.
35. The plasmid according to claim 32, wherein it has a length of between 9 and 11 kilobases.
36. The plasmid according to claim 32, wherein it has a length of between 9 and 10 kilobases.
37. The plasmid according to claim 32, wherein said heavy chain of the immunoglobulin is chimeric.
38. The plasmid according to claim 37, wherein said heavy chain of the immunoglobulin comprises a murine variable region and a human constant region.
39. The plasmid according to claim 38, wherein said murine variable region is VH62.
40. The plasmid according to claim 39, wherein said murine variable region VH62 is cloned from a mouse hybridoma secreting a monoclonal antibody with anti-tyroglobulin activity.
41. The plasmid according to claim 38, wherein said human constant region is Igγ1.
42. The plasmid according to claim 41, wherein said human constant region Igγ1 is cloned from the vector pNγ1.
43. The plasmid according to claim 32, wherein it comprises a promoter for lymphocytic cells.
44. The plasmid according to claim 43, wherein said promoter for lymphocytic cells is around 50 bp.
45. The plasmid according to claim 43, wherein said promoter for lymphocytic cells is a viral promoter.
46. The plasmid according to claim 45, wherein said viral promoter is around 742 bp.
47. The plasmid according to claim 32, wherein it comprises the polyadenylation sequence AATAAA.
48. The plasmid according to claim 32, wherein it comprises an Escherichia coli bacterial origin of replication.
49. The plasmid according to claim 32, wherein it expresses resistance to neomycin and it comprises the origin of replication pBR322.
50. The plasmid according to claim 32, wherein it does not comprise the replication origin SV40.
51. The plasmid according to claim 32, wherein said antigenic epitope is selected from the group consisting of p540 (ILAKFLHWL; SEQ ID NO: 3), p572 (RLFFYRKSV; SEQ ID NO: 4), pY572 (YLFFYRKSV; SEQ ID NO: 5), p865 (RLVDDFLLV; SEQ ID NO: 6) and pNP (ASNENMETM; SEQ ID NO: 7).
52. A recombinant plasmid having a sequence at least 90% homologous to SEQ ID NO: 1.
53. The recombinant plasmid according to claim 52, wherein it has a sequence at least 95% homologous to SEQ ID NO: 1.
54. The recombinant plasmid according to claim 52, wherein it has the sequence set forth in SEQ ID NO: 1.
55. A recombinant plasmid having a sequence at least 90% homologous to SEQ ID NO: 2.
56. The recombinant plasmid according to claim 55, wherein it has a sequence at least 95% homologous to SEQ ID NO: 2.
57. The recombinant plasmid according to claim 50, wherein it has the sequence set forth in SEQ ID NO: 2.
58. A formulation containing at least one plasmid according to claim 32 together with pharmaceutically acceptable excipients and coadjuvants.
59. A method for inducing an immunoresponse in a human or animal organism comprising the transfection of prokaryotic or eukaryotic cells ex vivo by means of a plasmid according to claim 32 and the subsequent inoculation of said prokaryotic or eukaryotic cells into said human or animal organism.
60. The method according to claim 59, wherein the cells to be transfected belong to the family of lymphocytes.
61. The method according to claim 60, wherein said cells are taken from the peripheral vessels of said human or animal organism.
62. The method according to claim 59, wherein said plasmid has the sequence SEQ ID NO: 1.
63. The method according to claim 59, wherein said plasmid has a sequence at least 95% homologous with respect to SEQ ID NO: 1.
64. A method for inducing an immunoresponse in a human or animal organism comprising the inoculation in vivo into said human or animal organism of a plasmid according to claim 32.
65. The method according to claim 64, wherein said plasmid has the sequence SEQ ID NO: 2.
66. The method according to claim 64, wherein said plasmid has a sequence at least 95% homologous to SEQ ID NO: 2.
67. The method according to claim 59, wherein the inoculation of the plasmid or of the prokaryotic or eukaryotic cells into said human or animal organism is carried out by means of injective or transmucosal administration.
US12/377,114 2006-08-10 2007-07-13 Plasmids with immunological action Abandoned US20100040648A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06118717.5 2006-08-10
EP06118717A EP1887084A1 (en) 2006-08-10 2006-08-10 Plasmids with immunological action
PCT/EP2007/057224 WO2008017568A1 (en) 2006-08-10 2007-07-13 Plasmids with immunological action

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/057224 A-371-Of-International WO2008017568A1 (en) 2006-08-10 2007-07-13 Plasmids with immunological action

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/116,686 Continuation-In-Part US8691959B2 (en) 2006-08-10 2011-05-26 Plasmids with immunological action

Publications (1)

Publication Number Publication Date
US20100040648A1 true US20100040648A1 (en) 2010-02-18

Family

ID=37575181

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/377,114 Abandoned US20100040648A1 (en) 2006-08-10 2007-07-13 Plasmids with immunological action
US13/116,686 Expired - Fee Related US8691959B2 (en) 2006-08-10 2011-05-26 Plasmids with immunological action

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/116,686 Expired - Fee Related US8691959B2 (en) 2006-08-10 2011-05-26 Plasmids with immunological action

Country Status (9)

Country Link
US (2) US20100040648A1 (en)
EP (2) EP1887084A1 (en)
JP (1) JP5491179B2 (en)
CN (2) CN101500604A (en)
AT (1) ATE533505T1 (en)
CA (1) CA2660324C (en)
ES (1) ES2377466T3 (en)
MX (1) MX2009001544A (en)
WO (1) WO2008017568A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2467978C1 (en) * 2011-10-24 2012-11-27 Юлия Алексеевна Щепочкина Crude mixture for producing structural material
RU2467975C1 (en) * 2011-10-24 2012-11-27 Юлия Алексеевна Щепочкина Crude mixture for producing structural material with curing thereof in calcium chloride solution

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583202A (en) * 1989-02-24 1996-12-10 The Regents Of The University Of California Antigenized antibodies and genes
US20040072240A1 (en) * 2000-07-21 2004-04-15 Kostas Kosmatopoulos Method for screening peptides for use in immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05199865A (en) * 1991-07-30 1993-08-10 Toshiba Corp Method for miniaturizing plasmid of bacterium belonging to genus pseudomonas
RS50101B (en) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for immunomodulation
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
WO2000061766A2 (en) 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
WO2000064488A2 (en) * 1999-04-27 2000-11-02 Eurogen Holding, S.A. Somatic transgene immunization and related methods
DE60230736D1 (en) * 2001-04-30 2009-02-26 Lilly Co Eli HUMANIZED ANTIBODIES WHICH RECOGNIZE THE BETA AMYLOID PEPTIDE &x9;
WO2005021595A1 (en) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
CN101115766B (en) * 2004-06-18 2013-05-08 印度免疫有限公司 Codon-optimized HPV16LI for salmonella vaccine strains against human papillomavirus type 16

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583202A (en) * 1989-02-24 1996-12-10 The Regents Of The University Of California Antigenized antibodies and genes
US20040072240A1 (en) * 2000-07-21 2004-04-15 Kostas Kosmatopoulos Method for screening peptides for use in immunotherapy

Also Published As

Publication number Publication date
US20120076807A1 (en) 2012-03-29
JP2010500013A (en) 2010-01-07
MX2009001544A (en) 2009-06-08
CN101500604A (en) 2009-08-05
CN105483152A (en) 2016-04-13
ATE533505T1 (en) 2011-12-15
CA2660324A1 (en) 2008-02-14
CA2660324C (en) 2014-09-09
US8691959B2 (en) 2014-04-08
EP1887084A1 (en) 2008-02-13
EP2049154A1 (en) 2009-04-22
EP2049154B1 (en) 2011-11-16
WO2008017568A1 (en) 2008-02-14
JP5491179B2 (en) 2014-05-14
ES2377466T3 (en) 2012-03-27

Similar Documents

Publication Publication Date Title
US11123427B2 (en) Immunoprotective primary mesenchymal stem cells and methods
Flatz et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity
CN102753200B (en) Influenza nucleic acids molecule and vaccine prepared therefrom
CN104640565B (en) Hepatitis B virus core protein and surface antigen protein and the vaccine comprising it
Kamili et al. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection
Kim et al. DNA vaccines against influenza viruses
Kantarcioglu et al. An update on the status of vaccine development for SARS-CoV-2 including variants. Practical considerations for COVID-19 special populations
US11453704B2 (en) Recombinant human replication-deficient adenovirus comprising a modified nucleic acid encoding the Marburg virus envelope glycoprotein
ES2902787T3 (en) DNAi vaccines and procedures for using the same
US8691959B2 (en) Plasmids with immunological action
EA009525B1 (en) Recombinant modified vaccinia virus ankara comprising the cowpox ati promoter and methods of use virus and promoter
CN110484515B (en) Vaccine vector for preventing FAdV-4 and NDV, and preparation method and application thereof
US20240226283A9 (en) Vaccination of hematopoietic stem cell donors with cytomegalovirus triplex composition
Wang et al. In vivo kinetics and biodistribution of a Hantaan virus DNA vaccine after intramuscular injection in mice
Khan Medical biotechnology
Mukhopadhyay et al. Review on Gene-Based Vaccines
Ansari GENERATION OF CHIMERIC RHINOVIRUSES PRESENTING SARS-COV-2 BROADLY NEUTRALIZING EPITOPES AND THEIR ANTIGENICITY CHARACTERIZATION
Sanghez et al. 430. Antibodies to Recombinant Human α-L-Iduronidase Enhance Uptake into Macrophages in Murine Mucopolysaccharidosis Type I
EA047158B1 (en) VACCINE FOR PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION
JP2023536160A (en) Modified Chikungunya virus and Sindbis virus and uses thereof
Llewellyn et al. 184. Next Generation TALENs Mediate Efficient Disruption of the CCR5 Gene in Human HSCs
CN105838738A (en) Self-complementary recombinant adeno-associated virus (scRAAV) carrier carrying CTAG1B/NY-ESO-1 tumor antigen gene, construction method and application thereof
WO2016130031A1 (en) Dna vaccine against h5n1 influenza virus, modified nucleotide sequence and use of the modified nucleotide sequence in vaccine manufacturing

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTERNATIONAL INVESTMENT AND PATENTS S.A.,LUXEMBOU

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GERLONI, MARA;REEL/FRAME:022577/0774

Effective date: 20090320

AS Assignment

Owner name: INTERNATIONAL INVESTMENT AND PATENTS S.A.,LUXEMBOU

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 022577 FRAME 0774. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ADDRESS IS 31, BOULEVARD GRANDE-DUCHESSE CHARLOTTE, LUXEMBOURG, LUXEMBOURG L-1331;ASSIGNOR:GERLONI, MARA;REEL/FRAME:022606/0257

Effective date: 20090320

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE